27 Feb / 24
Absci Announces Pricing of Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering price of $4.50 per share,
27 Feb / 24
Absci Announces Proposed Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock.
20 Feb / 24
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. TD Cowen 44 th Annual Health Care Conference in Boston, MA 
10 Jan / 24
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca.   In addition to joining Absci’s Board, Sir Pangalos will co-chair Absci’s Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI
Displaying 1 - 10 of 11
Popup Close
You’re leaving the Absci website. This link is provided for your convenience, but the content is the sole responsibility of its owner. Do you want to continue?
Return to the Absci website at any time by using the “Back” button on your web browser.

YES

NO

Popup Image